Company Overview and News

12
BioSpace Movers and Shakers for Oct. 15

2018-10-15 biospace
Pfizer – As global pharma giant Pfizer prepares for Albert Bourla to take over the reins of Pfizer from Chief Executive Officer Ian Read, the company has provided information on its senior leadership team.
BLCM JNCE ATRA JUNO CASC AGIO RETA ALDR CLVS

13
Bay State Life Sciences Companies Offer Strong Incentives Packages to Woo New Hires

2018-10-12 biospace - 1
For those looking for work, it’s good to know that some positions are in such demand that employers are falling all over themselves to offer hiring incentives. That’s the case with the biotech sector in Massachusetts, as many companies are dangling almost unheard-of benefits as incentives.
INFI NTGN AGIO

80
Deciphera Pharmaceuticals: Will This ASCO Winner Repeat At ESMO?

2018-09-20 seekingalpha - 1
The valuation gap with larger competitor Blueprint Medicines appears enticing, even after the latter's recent decline.
DCPH TSRO SHPG BPMC AMGN MRK SPPI AGIO HRTX PFE GSK

6
For Investors Seeking Exposure To Biotech, BB Biotech AG Might Be An Interesting Alternative To Funds

2018-09-18 seekingalpha - 1
Demographic factors as well as the rise of the global middle class back the long-term trend.
BBAGF GILD MYOV IONS CELG AGIO NBIX IBB

10
Biotech IPOs are booming, but is the frenzy almost over?

2018-09-11 sfgate
Biotechnology companies have been going public at a blistering pace this year, even as private investors are pouring more and more money into younger and younger startups.
NTGN JUNO AGIO

18
Movers and Shakers for Aug. 10

2018-09-10 biospace - 3
Agios Pharmaceuticals – Longtime Celgene veteran Jacqualyn (Jackie) Fouse has taken over the reins of Cambridge, Mass.-based Agios Pharmaceuticals. She will assume her the role of chief executive officer on Feb. 1, 2019, when current CEO David Schenkein steps down. Fouse has been serving on the Agios board of directors since December 2017. Fouse joined Celgene in 2010 and served as chief financial officer, and president of the company’s Hematology & Oncology franchise.
RGLS ALXN BCLI AGIO CRVS PTCT RDUS ALRN PFNX

10
Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position

2018-09-05 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) announced that it has appointed Dr. Jacqualyn Fouse as the company’s new chief executive officer (CEO) effective Feb 1, 2019. She will succeed Dr. David Schenkein, the current CEO.
EGRX QDEL CELGZ AGIO CELG

3
Celgene Vet Jackie Fouse Taking Over as CEO of Agios Pharmaceuticals; Companies Also Terminate Pr...

2018-09-05 biospace
One year after stepping down from her role as president and chief operating officer of Celgene, Jacqualyn (Jackie) Fouse has taken over the reins of Cambridge, Mass.-based Agios Pharmaceuticals. She will assume her new role on Feb. 1, 2019, when current CEO David Schenkein steps down.
AGIO

3
Agios, Celgene End Collaboration to Develop Cancer Treatment AG-881

2018-09-05 genengnews
Agios Pharmaceuticals and Celgene have agreed to terminate a three-year-old collaboration, with Agios obtaining sole global rights to AG-881, an oral inhibitor of both the isocitrate dehydrogenase-1 (IDH1) and IDH2 proteins, three months after presenting encouraging Phase I data in advanced glioma and other solid tumors. [Source: iStock/Ingram_Publishing]
AGIO

3
AGIO / Agios Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-09-05 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AGIO

3
AGIO / Agios Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-09-05 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AGIO

5
Agios names former Celgene executive Jacqualyn Fouse as next CEO

2018-09-04 channelnewsasia
REUTERS: Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.
CELGZ CELG AGIO BGEPF BG

5
Agios names former Celgene executive Jacqualyn Fouse as next CEO

2018-09-04 reuters
(Reuters) - Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.
CELGZ CELG AGIO BGEPF BG

5
Agios Announces Chief Executive Officer Succession Plan

2018-09-04 globenewswire
- David Schenkein, M.D., Agios Long-Time Chief Executive Officer, to Become Executive Chairman, Effective February 1, 2019 -
CELGZ AGIO CELG BGEPF BG

16
Constellation Pharmaceuticals Announces Appointments to Board of Directors

2018-09-04 globenewswire - 4
CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Dr. Elizabeth G. Tréhu and Steven L. Hoerter have been appointed to its Board of Directors.
INFI JNCE AGIO CNST CLVS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 00847X104